KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Assets (2017 - 2026)

Moderna (MRNA) has disclosed Non-Current Assets for 10 consecutive years, with $5.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 3.7% year-over-year to $5.7 billion; the TTM value through Mar 2026 reached $22.9 billion, down 5.17%, while the annual FY2025 figure was $5.8 billion, 4.12% down from the prior year.
  • Non-Current Assets hit $5.7 billion in Q1 2026 for Moderna, down from $5.8 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $12.5 billion in Q2 2022 and bottomed at $5.5 billion in Q3 2025.
  • Average Non-Current Assets over 5 years is $8.4 billion, with a median of $7.1 billion recorded in 2024.
  • Year-over-year, Non-Current Assets surged 1036.13% in 2022 and then crashed 46.66% in 2024.
  • Moderna's Non-Current Assets stood at $12.4 billion in 2022, then tumbled by 34.81% to $8.1 billion in 2023, then dropped by 25.4% to $6.0 billion in 2024, then fell by 4.12% to $5.8 billion in 2025, then dropped by 1.31% to $5.7 billion in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $5.7 billion, $5.8 billion, and $5.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.